Endocrine Abstracts

Contents

• 18th Annual Multidisciplinary NET Medical Symposium NANETS 2025
• • Basic Science
  • • Spatial and Transcriptional Profiling Reveals Immune Remodeling and Microenvironmental Heterogeneity in Benign and Malignant Pancreatic Neuroendocrine Tumors

      ea0116b1
    • Validation of Adversity-Linked Genes in Pancreatic Neuroendocrine Tumors

      ea0116b2
    • A SST14 based T-cell engager for the treatment of neuroendocrine tumors

      ea0116b3
    • Single-nucleus transcriptomic analysis of the tumor microenvironment in small intestinal NETs

      ea0116b4
    • Uncovering Filamin A as an Exosomal Biomarker in PanNET Through Integrative Tissue Proteomics

      ea0116b5
    • Tumor-Intrinsic Adaptations to Liver Microenvironment Drive Metastasis in Pancreatic and Small Intestinal Neuroendocrine Tumors

      ea0116b6
    • Changes in the Tumor Microenvironment of Well-Differentiated Metastatic Neuroendocrine Tumors might mediate resistance in patients treated with 177Lu-DOTATATE

      ea0116b7
    • Deciphering the Functionality of MAX Phosphorylation Dynamics in Pancreatic Neuroendocrine Tumors

      ea0116b8
    • Spatial Transcriptomics Reveals Local Subtype-Specific Identity and Signaling within Multifocal Small Intestinal Neuroendocrine Tumors

      ea0116b9
    • Allosteric ClpP agonist ONC206 alters mitochondrial metabolism, stress response and chromatin accessibility to elicit apoptosis in pheochromocytoma

      ea0116b10
  • Applied Basic Science
  • • Mechanisms and Models for Cdk5 dependent Neuroendocrine Tumors

      ea0116b11
    • Influence of patient cohort size on PFS prediction accuracy using baseline SSTR image models

      ea0116b12
    • Claudin 18.2 in pancreatic neuroendocrine tumors: a potential therapeutic target

      ea0116b13
    • Advanced 3D preclinical models of pancreatic neuroendocrine tumors: from bioprinting to precision-cut tumor slices

      ea0116b14
  • Clinical – Chemo/SSA/Biologics
  • • An ongoing phase 1 trial of obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression

      ea0116c1
    • Prognostic Significance of MEN1, ATRX, and DAXX Mutations in Pancreatic Neuroendocrine Tumors Treated with CAPTEM: Insights from a Multicenter Cohort

      ea0116c2
    • Investigator-Assessed Disease Progression in a Phase 2 Study of Paltusotine in Patients with Neuroendocrine Tumors and Carcinoid Syndrome

      ea0116c3
    • Multicenter Real-World Study of Treatment Patterns in Well-Differentiated Grade 3 (G3) Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

      ea0116c4
    • PPM1D as a Potential Driver of Myeloid Malignancy Transformation in Neuroendocrine Tumor (NET) Pts: An Underrecognized Malignant CHIPerpetrator?

      ea0116c5
    • TROP2 Expression in the Gastroenteropancreatic Neuroendocrine Tumors; An analysis of 179 patients

      ea0116c6
    • The Hidden Cost of Enzyme Therapy: Oxalate Nephropathy in a NET Patient with Pancreatic Insufficiency

      ea0116c7
    • DAREON®-7: Phase I open-label dose-escalation/-expansion study of first-line obrixtamig (BI 764532) plus chemotherapy in patients with DLL3-positive neuroendocrine carcinomas

      ea0116c8
    • Somatic genomic profiling of gastrointestinal neuroendocrine tumors: Implications for prognostication and therapeutic targeting

      ea0116c9
    • The Efficacy of Low-dose vs Standard-dose Everolimus in Patients with Advanced Neuroendocrine Tumors

      ea0116c10
    • The useful combination of capecitabine and temozolomide (CAPTEM) in metastatic lung carcinoid tumors

      ea0116c11
  • Clinical – Nuclear Medicine/Interventional Radiology/Imaging
  • • Randomized Embolization Trial for NeuroEndocrine Tumors (RETNET)

      ea0116c12
    • Safety and clinical implications of concurrent biopsy of neuroendocrine liver metastases at the time of liver-directed therapy

      ea0116c13
    • Efficacy of 177Lu-edotreotide vs everolimus in patients with grade 1 or grade 2 GEP-NETs: Phase 3 COMPETE trial (post hoc subgroup analyses)

      ea0116c14
    • Long-term Follow-up of PRRT-Naive Patients with GEP-NETs Treated with Targeted Alpha Therapy 212Pb-DOTAMTATE in the Phase 2 ALPHAMEDIX 02 Trial

      ea0116c15
    • Phase 2 Study of Targeted Alpha Therapy 212Pb-DOTAMTATE in Patients with Advanced Gastroenteropancreatic (GEP)-NETs Previously Treated with PRRT

      ea0116c16
    • 61Cu-NODAGA-LM3 versus 68Ga-DOTATOC in the same patients with neuroendocrine tumors: Preliminary results of the Phase I/II COPPER-PET-in-NET Trial

      ea0116c17
    • Patient Characteristics and Treatment Patterns With [177Lu]Lu-DOTA-TATE (177Lu-DOTATATE) In the US: A Real-World Assessment

      ea0116c18
    • [212Pb]VMT-alpha-NET for advanced SSTR+ NETs: safety and preliminary efficacy results from cohorts 1 and 2 of the dose escalation phase

      ea0116c19
    • Multi-center NCI-sponsored phase 1 study of triapine in combination with 177Lu-dotatate in patients with progressive well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

      ea0116c20
    • Single institution experience with [131I]MIBG for pheochromocytoma and paraganglioma: Long-term outcomes and dosimetry

      ea0116c21
    • Systematic Literature Review and Radiomics Quality Assessment for Lung, Adrenal, Thyroid and Pituitary Neuroendocrine Tumors

      ea0116c22
    • Efficacy and safety of [177Lu]Lu-edotreotide ([177Lu]Lu-DOTATOC) for the treatment of neuroendocrine tumors (NETs) - a systematic literature review (SLR) and meta-analysis

      ea0116c23
    • Safety of Transarterial Liver Directed Therapy for Metastatic Neuroendocrine Tumor for Patients with Carcinoid Heart Disease

      ea0116c25
    • Clinical outcomes following salvage PRRT in patients with metastatic neuroendocrine tumors

      ea0116c26
    • Efficacy and Safety of Peptide Receptor Radionuclide Therapy Retreatment (r-PRRT) Practices in Progressive Neuroendocrine Tumors (prog-NETs): Systematic Review and Meta-Analysis

      ea0116c27
    • Abstract unavailable

      ea0116c28
    • Correlation of dosimetry and toxicity for Lu177-DOTATATE in GEP-NETs

      ea0116c29
    • DISCO: Safety, Tolerability and Diagnostic performance of 64Cu-SARTATE compared to 68Ga-DOTATATE in patients with known or suspected neuroendocrine tumors

      ea0116c30
    • Abstract unavailable

      ea0116c31
    • Incidence of Peripheral Inserted Central Line Complications with Administration of 177Lutetium Dotatate

      ea0116c32
    • Somatostatin receptor expression on 68Ga-Dotatate imaging among patients with poorly differentiated extra-pulmonary neuroendocrine carcinomas: a prospective study

      ea0116c33
    • Outcomes of Peptide Receptor Radionuclide Therapy in Patients with Pheochromocytoma and Paraganglioma: A Center of Excellence Experience

      ea0116c34
  • Clinical – Surgery/Applied Pathology
  • • Care of Neuroendocrine Tumors: the Collaborative of Surgical Teams for NeuroEndocrine Tumors (CUTNETs)

      ea0116c35
    • The Natural History of Small Bowel Neuroendocrine Tumor (SBNET) Metastases

      ea0116c36
    • International expert consensus on perioperative management of carcinoid crisis

      ea0116c37
    • Association of Surgical Intervention with 30-Day Re-admission and Outcomes in Patients Hospitalized for Small Bowel Neuroendocrine Tumor-Related Obstruction

      ea0116c38
    • Primary Tumor Resection Is Associated With Improved Survival in Metastatic GI-NETs: A Retrospective Study in the Bronx, NY

      ea0116c39
    • Short-term post-operative outcomes after surgery for entero-pancreatic neuroendocrine tumors (NETs): a population-based analysis

      ea0116c40
    • Survival outcomes after surgery for entero-pancreatic neuroendocrine tumors: a population-based analysis

      ea0116c41
    • Risk Factors and Prognosis of Peritoneal Metastases in Small Bowel Neuroendocrine Tumor Patients

      ea0116c42
    • Mapping the evidence for surgical care of gastro-entero-pancreatic neuroendocrine tumors: a scoping review

      ea0116c43
    • Resection of Primary Pancreatic Neuroendocrine Tumors in the Metastatic Setting

      ea0116c44
    • Improving Outcomes for Neuroendocrine Patients: 25 year review of 1699 NET Surgical Cytoreduction Patients at a Single Institution

      ea0116c45
    • Evaluating the role of postoperative long-acting somatostatin analogue therapy in patients with metastatic neuroendocrine tumors undergoing surgical debulking

      ea0116c46
    • Role of Surgery in Patients with G1-G2 Pancreatic Neuroendocrine Tumors and Synchronous Liver Metastases

      ea0116c47
    • Pancreatic Neuroendocrine Tumors with Intraductal Growth: Unraveling a Rare Entity

      ea0116c48
    • Differential Expression of GLUT-1 and FASN Across Histological Grades of Pancreatic Neuroendocrine Neoplasms

      ea0116c49
    • Preoperative Predictors of New-Onset Diabetes Mellitus Following Distal Pancreatectomy for Non-functioning Pancreatic Neuroendocrine Tumours

      ea0116c50
  • Population Science
  • • Abstract unavailable

      Section
  • Other
  • • Abstract unavailable

      Section
  • Trials In Progress
  • • Abstract unavailable

      Section